Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytolysis (ADCC) Relative to Other Anti-CD20 mAbs

site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
Drug Category : Array
Conference Category : Array
Lead Author : Foley J, et al.
Published Date : 25/04/2023
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2023/04/Foley-AAN_2023.pdf
Download Text : Download
Popup Confirmation? :
astra-migrate-meta-layouts : set
Scroll to Top